Things for many people with breast cancer continue to improve, Elizabeth Tracey reports

Podcast: Download (Duration: 1:04 — 1.5MB)

Subscribe: RSS

Breast cancer is characterized by complexity, with receptor status and a host of other factors used to describe tumors and best treatments. Now a new study recounted by William Nelson, director of the Kimmel Cancer Center at Johns Hopkins, may change practice for women with one subset of the disease.

Nelson: For hormone receptor positive but HER2 negative breast cancer, if you added ribociclib to it was it of any advantage. 5000 folks randomized, presence or absence of ribociclib along with endocrine therapy for early stage breast cancer is an adjuvant therapy trial. And the combination improved disease free survival some 25% reduction in the relapses and death overall survival well on its way to becoming the standard treatment approach to this illness.  :29

Nelson recommends talking with your doctor to see if such a treatment regimen for breast cancer is one that’s appropriate for your tumor. At Johns Hopkins, I’m Elizabeth Tracey.